Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.

Michael J. Seider; Stephanie Shook; Corey J. Langer; Gwen Wyatt; William F. Demas; Afshin Rashtian; Cathy L Clausen; Jerry Derdel; Sean F Cleary; Christopher A. Peters; Ashok Ramalingam; James E. Clarkson; Michael B. Tomblyn; Rachel Rabinovitch; Lisa A. Kachnic; Lawrence B. Berk

doi:10.1200/JCO.2012.30.15_SUPPL.TPS9150

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.

Michael J. Seider
, Stephanie Shook
, Corey J. Langer
, Gwen Wyatt
, William F. Demas
, Afshin Rashtian
, Cathy L Clausen
, Jerry Derdel
, Sean F Cleary
, Christopher A. Peters
, Ashok Ramalingam
, James E. Clarkson
, Michael B. Tomblyn
, Rachel Rabinovitch
, Lisa A. Kachnic
, Lawrence B. Berk

University of Akron
RTOG Statistical Center, Philadelphia, PA
University of Pennsylvania
Michigan State University
Summa Health System
Kaiser Permanente
St. John's University
Mt Nittany Medical Center, State College, PA
Memorial Hospital of South Bend
Northeast Radiation Oncology Center, Dunmore, PA
University Hospitals of Cleveland
SRH Regional Cancer Center, Pascagoula, MS
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
University of Colorado Denver
Boston Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	30
DOIs	https://doi.org/10.1200/JCO.2012.30.15_SUPPL.TPS9150
State	Published - May 20 2012
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2012.30.15_SUPPL.TPS9150License: Unspecified

Cite this

Seider, M. J., Shook, S., Langer, C. J., Wyatt, G., Demas, W. F., Rashtian, A., Clausen, C. L., Derdel, J., Cleary, S. F., Peters, C. A., Ramalingam, A., Clarkson, J. E., Tomblyn, M. B., Rabinovitch, R., Kachnic, L. A., & Berk, L. B. (2012). Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517. Journal of Clinical Oncology, 30. https://doi.org/10.1200/JCO.2012.30.15_SUPPL.TPS9150

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517. / Seider, Michael J.; Shook, Stephanie; Langer, Corey J. et al.
In: Journal of Clinical Oncology, Vol. 30, 20.05.2012.

Research output: Contribution to journal › Article › peer-review

Seider, MJ, Shook, S, Langer, CJ, Wyatt, G, Demas, WF, Rashtian, A, Clausen, CL, Derdel, J, Cleary, SF, Peters, CA, Ramalingam, A, Clarkson, JE, Tomblyn, MB, Rabinovitch, R, Kachnic, LA & Berk, LB 2012, 'Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.', Journal of Clinical Oncology, vol. 30. https://doi.org/10.1200/JCO.2012.30.15_SUPPL.TPS9150

@article{edb54e7eb9954c1c8929008ac052cadd,

title = "Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.",

author = "Seider, \{Michael J.\} and Stephanie Shook and Langer, \{Corey J.\} and Gwen Wyatt and Demas, \{William F.\} and Afshin Rashtian and Clausen, \{Cathy L\} and Jerry Derdel and Cleary, \{Sean F\} and Peters, \{Christopher A.\} and Ashok Ramalingam and Clarkson, \{James E.\} and Tomblyn, \{Michael B.\} and Rachel Rabinovitch and Kachnic, \{Lisa A.\} and Berk, \{Lawrence B.\}",

note = "TPS9150 Background: Skeletal related events (SREs) diminish quality of life (QOL) as well as overall survival (OS) in patients with bone metastases, a common event in breast, lung and prostate cancer. SREs can be reduced or delayed by the use of bisphosphonates.",

year = "2012",

month = may,

day = "20",

doi = "10.1200/JCO.2012.30.15\_SUPPL.TPS9150",

language = "American English",

volume = "30",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.

AU - Seider, Michael J.

AU - Shook, Stephanie

AU - Langer, Corey J.

AU - Wyatt, Gwen

AU - Demas, William F.

AU - Rashtian, Afshin

AU - Clausen, Cathy L

AU - Derdel, Jerry

AU - Cleary, Sean F

AU - Peters, Christopher A.

AU - Ramalingam, Ashok

AU - Clarkson, James E.

AU - Tomblyn, Michael B.

AU - Rabinovitch, Rachel

AU - Kachnic, Lisa A.

AU - Berk, Lawrence B.

N1 - TPS9150 Background: Skeletal related events (SREs) diminish quality of life (QOL) as well as overall survival (OS) in patients with bone metastases, a common event in breast, lung and prostate cancer. SREs can be reduced or delayed by the use of bisphosphonates.

PY - 2012/5/20

Y1 - 2012/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.tps9150

U2 - 10.1200/JCO.2012.30.15_SUPPL.TPS9150

DO - 10.1200/JCO.2012.30.15_SUPPL.TPS9150

M3 - Article

VL - 30

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.

Disciplines

Access to Document

Other files and links

Cite this